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Abstract
In view of the evidence linking plasma high density lipoprotein (HDL)-cholesterol levels to a protective effect against coronary artery disease and the widespread use of fibrates in the treatment of hyperlipidemia, the goal of this study was to analyze the influence of fibrates on the expression of apolipoprotein (apo) A-Il, a major protein constituent of HDL. Administration of fenofibrate (300 mg/d) to 16 patients with coronary artery disease resulted in a marked increase in plasma apo A-Il concentrations (0.34±0.11 to 0.45+0.17 grams/liter; P < 0.01). This increase in plasma apo A-Il was due to a direct effect on hepatic apo A-Il production, since fenofibric acid induced apo A-Il mRNA levels to 450 and 250% of control levels in primary cultures of human hepatocytes and in human hepatoblastoma HepG2 cells respectively. The induction in apo A-Il mRNA levels was followed by an increase in apo A-Il secretion in both cell culture systems. Transient transfection experiments of a reporter construct driven by the human apo A-Il gene promoter indicated that fenofibrate induced apo A-II gene expression at the transcriptional level. Furthermore, several other peroxisome proliferators, such as the fibrate, Wy-14643 , and the fatty acid, eicosatetraynoic acid (ETYA), also induced apo A-Il gene transcription. Unilateral deletions and site-directed mutagenesis identified a sequence element located in the J-site of the apo A-Il promoter mediating the responsiveness to fibrates and fatty acids. This element contains two imperfect half sites spaced by 1 oligonucleotide similar to a peroxisome proliferator responsive element (PPRE). Cotransfection assays showed that the peroxisome proliferator activated receptor (PPAR) transactivates the apo A-Il promoter through this AII-PPRE. Gel retardation assays demonstrated that PPAR binds to the AlI-PPRE with an affinity comparable to its binding affinity to the acyl coA oxidase (ACO) -PPRE. In conclusion, in humans fibrates increase plasma apo A-Il concentrations by inducing hepatic apo A-Il production. Apo A-Il expression is regulated at the transcriptional level by fibrates and fatty acids via the interaction of PPAR with the AII-PPRE, Introduction Apolipoprotein (apo) A-I and apo A-II are the major protein constituents of high density lipoproteins (HDL), the plasma levels of which are inversely correlated with the incidence of coronary artery disease. Apo A-fl exists in plasma as a homodimer linked by an intradisulfide bond at residue 6 (1). The apo A-II protein sequence (1) , cDNA sequence (2) (3) (4) (5) , and genomic structure (5) (6) (7) (8) are known and the human gene has been localized on chromosome 1 (9) (10) (11) (12) . In man and other mammals, such as rats and mice, apo A-Il is mainly produced by the liver, and to a much lesser extent, by the intestine ( 13, 14) . The transcription of apo A-Il requires the synergistic action of factors, binding to a set of elements in the distal and proximal promoter (sites A to N) (15) (16) (17) (18) (19) (20) , as well as in the first intron of its gene (21) . The association, reported in certain mouse strains, between elevated apo A-Il levels and increased HDL size and HDL-cholesterol levels suggest that the plasma concentration of apo A-II might affect HDL structure and function (22, 23) . Apo A-Il may furthermore compete for the binding of HDL to the putative HDL receptor (24) . Recent in vivo studies demonstrate that overexpression of mouse apo A-II in transgenic mice enhances the development of atherosclerotic lesions (25, 26) , whereas overexpression of human apo A-Il in human apo A-I transgenic mice leads to a reduced protection against atherosclerosis (27) . This in vivo effect is consistent with the in vitro observations of a decreased capacity of apo A-II to stimulate cholesterol efflux (28) , and lecithin-cholesterol acyltransferase activity (29) , and suggests that apo A-II might reduce the protective effects of HDL against atherosclerosis. This hypothesis is further supported by the differential effects on the development of atherosclerosis of the two main lipoprotein (Lp) particles composing HDL, LpA-I, containing only apo A-I, and LpA-I:A-II, containing both apo A-I and A-II. Numerous data suggest that LpA-I plays the crucial role in the protection against atherosclerosis, whereas the LpA-I:A-II is less efficient (30) .
Fibrates, frequently used hypolipidemic agents, affect HDL metabolism in man (31) (32) (33) . These drugs belong to a group of chemicals called peroxisome proliferators, which also contain, besides fibrates, fatty acids, certain herbicides, and phtalate ester plasticizers. In rodents, all these compounds induce peroxisome proliferation (34) (35) (36) (37) and hepatomegaly, which may ultimately lead in these animals to hepatocarcinogenesis after prolonged administration (38, 39) . The peroxisome proliferation caused by these agents is, at least in part, the result of a transcriptional induction of enzymes of the ,3-oxidation pathway (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) . At present four distinct PPARs have been described a, /3, y, 6 (47, 54) . PPARs are members of the superfamily of nuclear hormone receptors, which after ligand activation, regulate the expression of genes containing specific response elements, called peroxisome proliferator response elements (PPREs) in their regulatory sequences (55, 56) . Functional PPREs have been characterized in several of the genes encoding enzymes involved in the peroxisomal /3-oxidation pathway, such as acyl-coA oxidase (ACO) and the trifunctional enzyme (55) (56) (57) (58) (59) (60) , in the cytochrome P450 4A6 gene (61, 62) , in the 3-hydroxy-3-methylglutaryl-coA synthase gene (63) , in the medium-chain acyl-coA dehydrogenase gene (64) , and in the aP2 gene (52) . Recently, we also identified a functional PPRE in the 5' upstream regulatory sequences (URS) of the apolipoprotein A-I gene (65).
In previous studies we analyzed the effects of fibrate treatment on apo A-II gene expression in rodents (66 Hepatocytes were obtained by a two-step collagenase perfusion as previously described (74) . Cells were resuspended in minimal essential medium with Earl's salts (GIBCO-BRL, Paisley, UK) supplemented with 10% FCS, 2 mM L-glutamine, 50 mg/ml gentamycine, seeded at a density of 1.5 x 105 cells/cm2 in 60-mm plastic culture dishes coated with 20 mg rat tail collagen type I (Sigma Chemical Co.) and incubated in a humified atmosphere of 5% C02/95% air at 370C. Medium was renewed after a 4-h adhesion period. After 20 h the medium was discarded and fenofibric acid (in DMSO, final concentration 0.5% vol/ vol) was added at the indicated concentrations in serum-free medium. No morphological differences in cell adhesion or cell toxicity (determined by the MTT [tetrazoliumi colorimetric test) (75) were observed between control and treated hepatocytes.
RNA analysis. RNA from cells was prepared as described by Chomczynski and Sacchi (76). Northern blot hybridizations and quantification of total cellular RNA were performed as described previously (66) . Apo A-fl mRNA was measured using a human apo A-Il cDNA clone (11) . A human GAPDH cDNA clone (77) was used as control. All probes were labeled by random priming (Boehringer Mannheim). Quantitative analysis was performed by scanning densitometry (BioRad GS670 densitometer).
Transient transfections and expression assays. Transfections in HepG2 cells were performed at 50-60% confluency by the calcium phosphate coprecipitation procedure with a mixture of plasmids which contained in addition to the reporter and expression vector(s), 0.5 Jsg of CMV-P-gal expression vector as a control for transfection efficiency.
All samples were complemented to an equal total amount of DNA. After 4 h cells were washed with PBS, and incubated for another 16 h with fenofibric acid, other fibrates or fatty acids in fresh medium containing 5% calf serum delipoproteinized by ultracentrifugation in KBr (1.21 grams/ml) and subsequently treated with AG-1-X8 resin (BioRad) plus activated charcoal. CAT activity was determined on cell extracts as described by Gorman et al. (78 (Fig. 1) .
Fibrates increase apo A-II mRNA and protein secretion in primary human hepatocytes and in the human hepatoblastoma cell line HepG2. To study the mechanism of induction of plasma apo A-Il concentrations in vivo, the regulation of apo A-fl expression by fibrates was studied in two different human cell culture systems. First, the effects of fenofibrate was studied using primary cultures of human hepatocytes. Addition of fenofibric acid for 24 h to the culture media induced the apo A-Il mRNA levels already near-maximally at a dose of 50 jLM (Fig.   2 A) . A maximal fivefold stimulation over control was observed at 500 jtM of fenofibric acid (Fig. 2 A) . No change in acyl coA oxidase (ACO) or GAPDH mRNA levels could be observed under these conditions (not shown and Fig. 2 A) . The induction of apo A-II mRNA levels was accompanied after 48 h by a significant increase in apo A-Il secretion in the culture medium (Fig. 2 B) . In contrast, apo E secretion in the culture medium remained constant under these conditions (Fig. 2 B) .
Next, it was investigated whether fenofibric acid also induces apo A-Il mRNA levels and protein secretion in the human hepatoblastoma cell line HepG2. When HepG2 cells were treated with 500 ,uM fenofibric acid, apo A-Il mRNA levels increased to 154 and 248% of control values at 24 and 48 h, respectively (Fig. 3, A and B) . To verify whether this induction (Fig. 4 A) . The potent fibrate derivative Wy-14643 induced apo A-II promoter activity to 195±15% and 180±18% at concentrations of 30 and 100 pM respectively (Fig. 4 A) . By contrast the RSV-driven CAT activity remained unchanged under these conditions (DMSO: 100±11%; FF 500 MM: 93+13%). These results clearly indicate that the increase in apo A-Il production in human liver after fibrates occurs at the transcriptional level.
To investigate whether the increased expression of the apo A-II promoter after fenofibrate was a particular feature of fibrates or a more general effect of peroxisome proliferators and fatty acids, the effects of different peroxisome proliferators on apo A-II gene transcription were analyzed after transient transfection of the -911/ + 160A-II-CAT construct (Fig. 5) . When different fibrates were compared, the expression of the apo A-II promoter was induced by fenofibrate (1.5-fold) and by the potent PPAR activator, Wy-14643 (1.8-fold) (80) . The sulfurcontaining fatty acid analogue tetradecylthioacetic acid (TTA) did not affect apo A-II promoter activity, whereas the arachidonic acid derivative 5,8,11,14- (Fig. 7 A) and its activity was compared to the activity of the wild-type (wt) construct ( -91 1 / + 160AII-CAT) transfected in HepG2 cells (Fig. 7, B and D) .
Mutation of the J-site DR-I sequence not only resulted in a loss of inducibility of apo A-LI promoter regulation by PPAR and fenofibric acid, but also in a strong decrease in baseline level CAT activity (Fig. 7 D) . This decrease in basal CAT activity suggests that the J-site not only mediates the transcriptional response to PPAR and peroxisome proliferators, but also is a strong site driving the basal expression of the apo A-II promoter.
To prove that the J site could function as a PPRE in front of a heterologous promoter, the J, site was cloned as a monoand trimer in front of the heterologous thymidine kinase (TK) promoter to generate the construct J,-TK-CAT (Fig. 7A ). Upon cotransfection of these constructs with mPPARa into HepG2 cells it was evident that the J site could transmit PPAR activation to this heterologous promoter (Fig. 7 C) PPAR/RXR heterodimers bind to the AII-PPRE in the J site of the apo A-Il gene. Next, it was investigated whether PPAR could bind to the AII-PPRE by electrophoretic mobility shift assays (EMSA). Incubation of a double-stranded oligonucleotide corresponding to the J site (Jw,) and spanning sequences from -737 to -715 relative to the transcription initiation site of the apo A-II gene with in vitro produced haPPARy and mRXRa resulted in the formation of a retarded complex (Fig.  9) . Similar binding data were obtained when xPPARa was used instead of haPPARy, and mRXRa was replaced by mRXR/3 (data not shown), demonstrating that the AII-PPRE was capable of binding different PPAR/RXR heterodimers. By contrast, haPPARy homodimers were incapable of binding to the J,, site (Fig. 9, lane 4) . On a labeled double-stranded oligonucleotide containing the mutated AII-PPRE (AIV-PPREm,) no binding of haPPAR-y and mRXRa heterodimers was observed, thereby confirming and extending the results of our transfection experiments (Fig. 9, lane 8) .
To demonstrate that the proteins binding to the AII-PPRE were identical to those binding to the classical ACO-PPRE, cross competition experiments were performed next. In a first experiment, it was tested whether cold ACO-, AII-PPREwt-and AII-PPREmt-oligonucleotides could compete with the binding of haPPARy/mRXR/3 heterodimers to the labeled AIIWPPRE oligonucleotide (Fig. 9 lanes 11-22) . Both the ACO and AIIPPREWt sequences competed, whereas the AII-PPREmt did not compete with the binding of haPPARy/mRXRa heterodimers to the AII-PPRE,^. Interestingly, the competition was as efficient with the cold ACO-PPRE and AII-PPRE~t oligonucleotides, suggesting that the AII-PPRE is a strong PPRE. In a second experiment, cross competition was performed using ACO-PPRE as a probe (data not shown). Also in this experiment equivalent molar ratios of cold ACO or All-PPREt oligonucleotide could prevent haPPARy/mRXRa heterodimers from binding to the ACO-PPRE. In contrast, cold AII-PPREm. oligonucleotide could not compete for the binding of haPPAR'y/ mRXRa heterodimers from binding to the ACO-PPRE.
Discussion
In view of the evidence linking elevated levels of HDL-cholesterol to a protective effect against the development of coronary artery disease and the widespread use of fibrates in the treatment of diet-resistant hyperlipidemia, one of the goals of our research was to determine whether fibrates regulate the expression of apo A-IT, one of the major protein constituents of HDL, and to understand the molecular mechanisms underlying its regulation. Despite the beneficial effects of these drugs on apo B-containing lipoproteins, results from most of the clinical studies indicate that fibrates favor the occurrence of a HDL profile consisting of an augmentation of LpA-I/A-II particles, which are less (81) or, alternatively and perhaps more likely, to the presence of (a) natural ligand(s), constitutively activating PPAR in these cells. It can, however, not be excluded that both mechanisms act together, since fibrates could potentiate the positive effect of PPAR on the truncated apo A-II promoter constructs. By using unilateral 3' deletions of the apo A-I1 distal enhancer region, we localized the responsive region in the J site (19) . This site was found to contain two imperfect copies of a motif related to the consensus steroid hormone receptor half-site TGACCT arranged with a spacing of 1 nucleotide (or DR-1). Previous studies have shown that this J element forms two DNA-protein complexes in hepatocyte nuclear extracts, termed AIIJl and AIIJ2, the last of which has some similarities with NF-BA-1 (82, 83) . Furthermore, several orphan nuclear receptors, such as HNF-4, EAR2, EAR3, and ARP-1, have been shown to interact with this J site (20, 82 induces, whereas EAR-2, EAR-3, and ARP-l reduce apo A-II gene transcription upon binding to this element (20) . In view of the binding of multiple nuclear hormone receptors to this J element, it was no surprise that PPAR could also interact with this element. Indeed, site-directed mutagenesis experiments demonstrated that this DR-I motif mediates the effects of PPAR and fibrates on apo A-II gene expression, whereas EMSA experiments indicated that PPAR/RXR heterodimers bind to the All-PPRE. Moreover, cross-competition experiments indicated that the All-PPREt binds PPAR with a similar affinity as the classical ACO-PPRE. These data hence implicate unequivocally PPAR in the response of the apo A-II gene to fibrate hypolipidemic drugs. In view of the proposed role of PPARs in mediating the effects of nutrition on gene expression it is tempting to speculate that nutritional effects on apo A-II gene expression also might be mediated via transcription factors belonging to the PPAR family. The induction of apo A-II promoter activity by certain fatty acid derivatives is an argument in support of this hypothesis. More detailed experiments to study the effects of various nutritional compounds on apo A-II expression are currently undertaken in our laboratory.
In contrast to the increase in apo A-TI mRNA levels in human hepatocytes and hepatoma cells, hepatic apo A-II mRNA levels decrease after in vivo administration of fibrates to rodents (66) . However, in rat liver the decrease in apo A-TI mRNA levels was not associated with altered transcription activity of the apo A-II gene, whereas in human liver increased apo A-H mRNA levels are linked to PPAR-mediated induction of apo A-II gene transcription. The different mechanisms involved in this species-specific opposite regulation of apo A-II mRNA levels are unclear at present, but several possible hypothesis can be forwarded. First, differences may exist between species in either the cis-acting elements, involved in these regulatory processes, or in the general promoter structure, leading to the absence of transcriptional regulation in rats, but not in humans. Second, qualitative and/or quantitative differences in trans-acting factors present in rodent or human liver may contribute to species-specific responses to certain agents. This is, however, less likely to explain the differential response to fibrates. In fact, it is clearly established that both rat and man produce multiple PPARs, the transcription factors involved in mediating the genomic response to peroxisome proliferators. Finally, species-specific metabolic differences could also affect the response to fibrates. In rodents these compounds act by inducing the expression of several genes coding for peroxisomal enzymes which results in a strong proliferation of peroxisomes and an extreme hepatomegaly (40, 41, 44, 84) . In contrast to rodents, the expression of the ACO gene remains constant in human hepatocytes treated with fenofibrate (85) , thereby indicating that fibrates have no or only a very limited capacity to induce peroxisomal enzymes in humans, as has been suggested previously by several authors (34) (35) (36) (37) . Since it is hypothesized that, at the cellular level, fibrates act indirectly probably by affecting intermediary steps of intracellular lipid metabolism (34) , it is conceivable that species-specific differences in intracellular metabolic responses to fibrates may differently affect gene expression via transcriptional or post-transcriptional regulatory mechanisms.
From these data, as well as from previous studies from our and other laboratories, it becomes increasingly evident that PPARs not only play an important role in the control of intracellular lipid metabolism and /3-oxidation, but also have a wide impact on lipid transport and lipoprotein physiology. When one considers HDL metabolism, it is evident that PPAR not only controls expression of apo A-II, but also the production rate of apo A-I, the other major protein component of HDL. In previous studies, we have indeed shown that PPAR and its activators have also a complex effect on the expression of apo A-I. On the one hand, fibrates exert a negative and probably PPARindependent effect on apo A-I gene transcription mediated by sequence elements located in the apo A-I basal promoter. On the other hand, this effect is counteracted by a PPAR-dependent positive effect mediated by a PPRE located in the A-site of the apo A-I promoter (65). In man this delicate interplay of regulation through the PPAR binding A site and the apo A-I basal promoter can result in a variable regulation of the entire apo A-I promoter depending upon the cellular context. Fibrates and PPAR not only have major effects on the metabolism of HDL particles, but they also affect the metabolic fate of apo B containing particles. In fact, we showed that fibrates diminish hepatic production of apo C-III, a mechanism which may lie at the basis of the hypotriglyceridemic action of these compounds (85) . Indeed, due to the reduced apo C-III concentration, both LPL-mediated lipolysis as well as, receptor-mediated clearance of triglyceride-rich particles will be improved, resulting in lowering of plasma triglyceride concentrations.
In conclusion, the results from these studies show that in humans apo A-II plasma concentrations increase upon treatment with fibrates, as a result of a PPAR-mediated induction of apo A-II gene transcription leading to an increase in hepatic apo A-II production. The regulation of the apo A-II gene by fibrates is another example indicating that, unlike in rodents, fibrates/ PPAR can modulate gene expression in humans without the concurrent induction of peroxisomal enzymes.
